

BOB ICB and Frimley ICB Priorities Committee Clinical Commissioning Policy Statement

Policy Number/ Name	BOBFPC111 Treatment with Anti-VEGF agents for Neovascular (Wet) Age-Related Macular Degeneration in patients with 'one good eye'
Date of BOBFPC Recommendation	July 2022

For the purpose of this policy, the good eye would be the only eye that, for example, enables driving vision or the ability to work or take medications safely, because the fellow eye is damaged with, for example, reduced visual field / reduced vision.

- The Buckinghamshire, Oxfordshire, and Berkshire West ICB and Frimley ICB Priorities Committee recommends that treatment with anti-vascular endothelial growth factor (anti-VEGF) agents, if provided by the manufacturer with the discount agreed in the patient access scheme, should be considered for patients with neovascular (active wet) age-related macular degeneration (AMD) in patients who have only one good eye that meets all the following criteria:
 - the best-corrected visual acuity is better than **6/96**
 - there is no permanent structural damage to the central fovea
 - the lesion size is less than or equal to 12 disc areas in greatest linear dimension
 - there is evidence of recent disease progression (blood vessel growth, as indicated by fluorescein angiography, or recent visual acuity changes)

If patients and their clinicians consider there to be a range of suitable treatments, the least expensive treatment should be chosen, including available biosimilars. Relevant factors that should be taken account of include treatment cost and patient visits, patient co-morbidities, service capacity and delivery.

Clinical Codes:

ICD10 Diagnosis:

H35.3 Degeneration of macula and posterior pole

OPCS Procedure code:

C79.4 Injection into vitreous body NEC

OPCS Laterality code:

Z94.1 Bilateral

Z94.2 Right sided operation

Z94.3 Left sided operation

Z94.4 Unilateral operation

Z94.5 Specified laterality NEC

Z 94.6 Laterality NEC

Using the diagnosis code alone, it is not possible to identify if the degeneration is in one or both eyes, or which eye. The OPCS procedure code above would be present in the clinical record as would the laterality code, the laterality code would be in a secondary position and will indicate which eye was treated:

The above OPCS code C79.4 would also be accompanied by a code to indicate the type of drug (X82% - X98%), the code will depend on the drug used.

NOTES:

- Potentially exceptional circumstances may be considered by a patient's ICB where there is evidence of significant health status impairment (e.g. inability to perform activities of daily living) and there is evidence that the intervention sought would improve the individual's health status.
- This policy was developed and recommended by Thames Valley Priorities Committee which was the predecessor of Buckinghamshire, Oxfordshire, and Berkshire West ICB and Frimley ICB Priorities Committee. Amendments have been approved by BOB APC.
- This policy will be reviewed in the light of new evidence or new national guidance, e.g. from NICE.
- BOBFPC clinical policies can be viewed at [Clinical Commissioning Policies & IFRs | BOB ICB](#)

Version	Date	Reason for change
Version 1	July 2022	New policy. Approved by BOB APC (not reviewed by BOBFPC)